A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus

Twelve children infected with the human immunodeficiency virus were treated orally with indinavir, stavudine, plus didanosine for 12 to 48 weeks. Therapy was limited in some cases by nonadherence, intolerance, toxicity, and virologic failure. Marked increases in CD4+ lymphocyte counts and decreases...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of pediatrics 1998-03, Vol.132 (3), p.543-546
Hauptverfasser:	Kline, Mark W., Fletcher, Courtney V., Harris, Alice T., Evans, Kim D., Brundage, Richard C., Remmel, Rory P., Calles, Nancy R., Kirkpatrick, Suzanne B., Simon, Cara
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adolescent Anti-HIV Agents - administration & dosage Anti-HIV Agents - adverse effects Anti-HIV Agents - pharmacokinetics Biological and medical sciences CD4 Lymphocyte Count Child Child, Preschool Chromatography, High Pressure Liquid Didanosine - administration & dosage Didanosine - adverse effects Didanosine - pharmacokinetics Drug Therapy, Combination Female Grade 4 HIV Infections - drug therapy Human viral diseases Humans Indinavir - administration & dosage Indinavir - adverse effects Indinavir - pharmacokinetics Infectious diseases Male Medical sciences Narcotics Organic Chemistry Pilot Projects RNA, Viral - blood Sampling Stavudine - administration & dosage Stavudine - adverse effects Stavudine - pharmacokinetics Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Twelve children infected with the human immunodeficiency virus were treated orally with indinavir, stavudine, plus didanosine for 12 to 48 weeks. Therapy was limited in some cases by nonadherence, intolerance, toxicity, and virologic failure. Marked increases in CD4+ lymphocyte counts and decreases in plasma human immunodeficiency virus RNA concentrations suggest that the regimen has potent antiviral activity. (J Pediatr 1998;132:543-6)
ISSN:	0022-3476 1097-6833
DOI:	10.1016/S0022-3476(98)70039-3